bevacizumab

• 

Atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer

By Sharon Kell|2019-06-03T08:08:23+00:003 Jun 2019|Drug treatments|

Results from this phase III trial of atezolizumab plus bevacizumab [...]

Read More

Comments Off on Atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer

• 

Bevacizumab plus erlotinib combination for advanced HLRCC

By Sharon Kell|2019-04-01T08:42:00+00:001 Apr 2019|Drug treatments|

A recent study, published in Cancer Research and Treatment in [...]

Read More

Comments Off on Bevacizumab plus erlotinib combination for advanced HLRCC

• 

ASCO GU 2019: Atezolizumab and bevacizumab in non-clear cell kidney cancer and sarcomatoid kidney cancer

By Sharon Kell|2019-02-26T12:51:10+00:0026 Feb 2019|Subtypes of RCC|

Results from this trial for patients with non-clear cell renal [...]

Read More

Comments Off on ASCO GU 2019: Atezolizumab and bevacizumab in non-clear cell kidney cancer and sarcomatoid kidney cancer

• 

Combination bevacizumab plus temsirolimus for second-line treatment of metastatic kidney cancer

By Sharon Kell|2018-11-15T14:42:24+00:0015 Nov 2018|Drug treatments|

A recent phase 2 study evaluated the combination of bevacizumab [...]

Read More

Comments Off on Combination bevacizumab plus temsirolimus for second-line treatment of metastatic kidney cancer

• 

Safety and tolerability of atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer

By Sharon Kell|2018-11-05T11:24:08+00:005 Nov 2018|Drug treatments|

The combined safety results of two studies with the atezolizumab [...]

Read More

Comments Off on Safety and tolerability of atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer

Potential biomarkers may predict response to TKIs in metastatic kidney cancer

By Sharon Kell|2018-08-17T16:00:41+00:0017 Aug 2018|Drug treatments|

A recent study published in Clinical Cancer Research and conducted in [...]

Read More

Comments Off on Potential biomarkers may predict response to TKIs in metastatic kidney cancer

• 

Patient-reported outcomes for atezolizumab plus bevacizumab combination

By Sharon Kell|2018-06-07T14:45:15+00:007 Jun 2018|Drug treatments|

Patient-reported outcomes from the phase 3 IMmotion151 study, which assessed [...]

Read More

Comments Off on Patient-reported outcomes for atezolizumab plus bevacizumab combination

Combination therapies for kidney cancer

By Sharon Kell|2018-02-21T08:54:59+00:0021 Feb 2018|Uncategorized|

The following is a Practice Update interview with Dr Hans Hammers, Associate [...]

Read More

Comments Off on Combination therapies for kidney cancer

Atezolizumab plus bevacizumab combination is positive for untreated metastatic kidney cancer

By Sharon Kell|2018-02-06T15:34:35+00:006 Feb 2018|Drug treatments|

The combination of immunotherapy atezolizumab (Tecentriq) with targeted therapy bevacizumab [...]

Read More

Comments Off on Atezolizumab plus bevacizumab combination is positive for untreated metastatic kidney cancer

Positive interim results for atezolizumab plus bevacizumab combination in advanced RCC

By Sharon Kell|2017-12-12T14:01:05+00:0012 Dec 2017|Drug treatments|

Interim results from the phase III IMmotion151 study to assess [...]

Read More

Comments Off on Positive interim results for atezolizumab plus bevacizumab combination in advanced RCC